Evidence map›Paper›PMID 30340625›Full record

ArticleTrials2018

Adolescent depression: Study protocol for a randomized, controlled, double-blind multicenter parallel group trial of Bright Light Therapy in a naturalistic inpatient setting (DeLight).

Martin Holtmann, Laura Mokros, Inken Kirschbaum-Lesch, Michael Kölch, Paul L Plener, Christian Ruckes, Michael Schulte-Markwort, Tanja Legenbauer

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. New Somatic Treatments for Child and Adolescent Depression.Current treatment options in psychiatry · 2019
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Martin HoltmannClinic for Child and Adolescent Psychiatry, LWL University Hospital Hamm of the Ruhr-University Bochum, Heithofer Allee 64, 59071, Hamm, Germany. martin.holtmann@lwl.org.
Laura MokrosClinic for Child and Adolescent Psychiatry, LWL University Hospital Hamm of the Ruhr-University Bochum, Heithofer Allee 64, 59071, Hamm, Germany.
Inken Kirschbaum-LeschClinic for Child and Adolescent Psychiatry, LWL University Hospital Hamm of the Ruhr-University Bochum, Heithofer Allee 64, 59071, Hamm, Germany.
Michael KölchDepartment Child and Adolescent Psychiatry and Psychotherapy, Brandenburg Medical School, Neuruppin, Germany.
Paul L PlenerDepartment of Child and Adolescent Psychiatry and Psychotherapy, Ulm University, Ulm, Germany.
Christian RuckesInterdisciplinary Centre for Clinical Trials, Mainz University, Mainz, Germany.
Michael Schulte-MarkwortDepartment Child and Adolescent Psychiatry, Hamburg University, Hamburg, Germany.
Tanja LegenbauerClinic for Child and Adolescent Psychiatry, LWL University Hospital Hamm of the Ruhr-University Bochum, Heithofer Allee 64, 59071, Hamm, Germany.
Ruhr University Bochum · DEJohannes Gutenberg University Mainz · DELWL-Universitätsklinik Hamm · DEMedizinische Hochschule Brandenburg Theodor Fontane · DEUniversität Hamburg · DEUniversität Ulm · DE

Funding

Bundesministerium für Bildung und Forschung 01KG1713
6 · The paper itself

Abstract

backgroundDepressive disorders are among the most prominent health problems in youth. Even with the best available pharmacological and non-pharmacological treatments, remission rates are low. Without early treatment, depression in youth is associated with a high risk of symptom progression, chronicity, co-morbidity, and suicidal behavior. Thus, adolescent depression is a prime candidate for innovation in treatment. In depressive adults, meta-analytic evidence has proven that bright light therapy (BLT) is a potent low-threshold intervention, promising due to easy application, low side effects, and optimized compliance. In adolescents, studies with small samples show promising effects. This randomized controlled trial will examine the effectiveness of BLT in youth inpatients. METHODS/

designIn this randomized, controlled, double-blind multicenter parallel group trial, morning BLT is applied for four weeks in addition to treatment as usual (TAU) for depressed youth inpatients (daily morning exposure to bright light via light-emitting glasses, 10,000 lx, for 30 min) and will be compared to a control condition (placebo light treatment, red light, identical light glasses). The primary objective is to assess whether BLT reduces symptoms of depression in youth with greater effect compared to placebo light therapy. Secondary objectives are to examine the impact of BLT on responder status, application of antidepressant medication, and further depression-related symptoms (sleep, activity, quality of life, satisfaction with health, general psychopathology, alertness, and circadian function). N = 224 patients will be recruited in a naturalistic inpatient setting. A follow-up will be carried out after three and six months. DISCUSSION: The study aims to discuss and evaluate BLT as an additive method supporting standardized clinical procedures dealing with severe to moderate depressive symptoms in youth.

trial registrationGerman Clinical Trials Register, DRKS00013188 . Registered on November 30, 2017.

Indexed as

Randomized Controlled Trials as TopicAdolescentBehavior Rating ScaleDepressionDouble-Blind MethodHumansMulticenter Studies as TopicPhototherapyQuality of LifeBright light therapyDepression in youthInpatientsTreatment

Identifiers

PMID30340625
PMCPMC6194631
OpenAlexW2897465210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.